Asset Details
Do you wish to reserve the book?
C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma
Do you wish to request the book?
C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma
2020
Overview
Supratentorial ependymoma (ST-EPN) is a type of malignant brain tumor mainly seen in children. Since 2014, it has been known that an intrachromosomal fusion
C11orf95-RELA
is an oncogenic driver in ST-EPN [Parker et al. Nature 506:451–455 (2014); Pietsch et al. Acta Neuropathol 127:609–611 (2014)] but the molecular mechanisms of oncogenesis are unclear. Here we show that the C11orf95 component of the fusion protein dictates DNA binding activity while the RELA component is required for driving the expression of ependymoma-associated genes. Epigenomic characterizations using ChIP-seq and HiChIP approaches reveal that C11orf95-RELA modulates chromatin states and mediates chromatin interactions, leading to transcriptional reprogramming in ependymoma cells. Our findings provide important characterization of the molecular underpinning of
C11orf95-RELA
fusion and shed light on potential therapeutic targets for
C11orf95-RELA
subtype ependymoma.
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
